HUMA
$1.16
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Intraday
Recent News
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential
How the DoD funding move ties into Humacyte’s investment story The latest U.S. Department of Defense appropriations and authorization bills set aside funding to assess biologic vascular repair technologies, directly spotlighting Humacyte (HUMA) and its FDA approved Symvess graft for extremity vascular trauma. See our latest analysis for Humacyte. Humacyte’s recent Department of Defense support arrives after a mixed trading stretch, with a 1 day share price return of 12.87% and a year to date...
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.
Why Humacyte (HUMA) Is Up 19.6% After New DoD Funding For Biologic Vascular Repair
In February 2026, Humacyte announced that the U.S. Department of Defense’s Fiscal Year 2026 Appropriations Act allocates dedicated funding to evaluate and incorporate biologic vascular repair technologies, aligning with prior National Defense Authorization Act language urging integration of FDA-approved breakthrough vascular repair options for traumatic extremity arterial injuries. This support shines a spotlight on Humacyte’s Symvess®, currently the only FDA-approved human-derived...
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index shedding 0.6% a